Overview: HBV DNA Quantitative Ultra TestIntroduction: The HBV DNA Quantitative Ultra Test quantifies hepatitis B viral DNA to monitor infection severity, preventing liver damage. Following 2023 AASLD guidelines, it uses PCR for high sensitivity, aiding in infectious disease screening. This test is critical for guiding antiviral therapy, assessing disease progression, and improving outcomes in virology for patients with chronic hepatitis B.
Other Names: HBV DNA Ultra Assay, Quantitative HBV PCR Test.
FDA Status: Laboratory-developed test (LDT), meeting virology standards for diagnostic accuracy.
Historical Milestone: HBV DNA testing began in the 1990s with PCR development. Ultra-sensitive PCR assays improved in the 2000s, enhancing viral load monitoring.
Purpose: Monitors hepatitis B infection severity, guides antiviral therapy, and quantifies HBV DNA in patients to prevent liver damage.
Test Parameters: 1. HBV DNA (Quantitative)
Pretest Condition: No fasting required. Collect whole blood, plasma, or serum at any time. Report history of hepatitis B, treatment status, or symptoms like fatigue.
Specimen: 2-5 mL whole blood (EDTA), 2-4 mL plasma (EDTA), or 2-5 mL serum (SST). Centrifuge within 1 hour. Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document fatigue, liver pain, or history of chronic hepatitis B. Include current medications, especially antivirals, and treatment history.
Consent: Written consent required, detailing the tests purpose, monitoring implications, and potential need for treatment adjustments.
Procedural Considerations: Uses ultra-sensitive PCR to quantify HBV DNA levels. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Improper sample handling, contamination, or low viral load can affect results. Antiviral therapy may suppress DNA levels.
Clinical Significance: High HBV DNA levels indicate active infection, guiding antiviral therapy. Low or undetectable levels suggest treatment response or inactive disease.
Specialist Consultation: Consult a hepatologist for result interpretation and antiviral therapy planning.
Additional Supporting Tests: HBsAg, anti-HBc, or liver function tests to monitor hepatitis B status.
Test Limitations: Low viral loads may be undetectable. Clinical correlation and serial testing are needed.
References: AASLD Hepatitis B Guidelines, 2023; Hepatology, Lok AS, 2022.
